Clinical Trial

Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Study acronym: CNN-BC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 4, 2024 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this phase II study, eligible patients will be treated with maximal tumor resection and then started treatment within 8 weeks. Chemotherapy, Nivolumab and radiotherapy (RT) will be started on day one. Chemotherapy will be administered weekly during radiotherapy. Radiotherapy will be performed from Monday to Friday for five weeks. Nivolumab will be administered for one year (13 infusions). Patients will have the complete tumour assessment by computed tomography scan (CT-scan) and cystoscopy up to 5 years after radiotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-01-10; most recent amendment 2024-10-03.
Status change: Not Yet Recruiting → Recruiting 2024-03-06
Trial Details
NCT Number NCT05203913
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Muscle-Invasive Bladder Carcinoma
Enrollment 32 participants
Start Date 2023-05-01
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2024-10-04